

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/904,782	07/13/2001	Suresh K. Tikoo	293102002900	1838	
25226 MORRISON &	7590 12/28/2006 2 FOERSTER LLP	EXAMINER			
755 PAGE MILL RD			HILL, MYRON G		
PALO ALTO, CA 94304-1018			ART UNIT	PAPER NUMBER	
			1648		
				<u> </u>	
			MAIL DATE	DELIVERY MODE	
			12/28/2006	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
09/904,782	TIKOO, SURESH K.	
Examiner	Art Unit	
Myron G. Hill	1648	

Before the Filling of all Appeal Brief	Examiner	Art Unit					
	Myron G. Hill	1648					
The MAILING DATE of this communication appe	ears on the cover sheet with the c	correspondence add	ress				
THE REPLY FILED 29 September 2006 FAILS TO PLACE THI	S APPLICATION IN CONDITION F	OR ALLOWANCE.					
1. The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Not a Request for Continued Examination (RCE) in compliant time periods:	wing replies: (1) an amendment, aff tice of Appeal (with appeal fee) in o ce with 37 CFR 1.114. The reply mo	idavit, or other eviden compliance with 37 Cl	ce, which FR 41.31; or (3)				
 a)	Advisory Action, or (2) the date set forth						
no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN							
TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
 The Notice of Appeal was filed on <u>29 September 2006</u>. A of the date of filing the Notice of Appeal (37 CFR 41.37(a appeal. Since a Notice of Appeal has been filed, any repl AMENDMENTS)), or any extension thereof (37 CFI	R 41.37(e)), to avoid o	dismissal of the				
3. The proposed amendment(s) filed after a final rejection,			ecause				
 (a) ☐ They raise new issues that would require further co (b) ☐ They raise the issue of new matter (see NOTE below 		i E below),					
(c) They are not deemed to place the application in be appeal; and/or	• •	ducing or simplifying	the issues for				
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)),		ected claims.					
4. The amendments are not in compliance with 37 CFR 1.1		mpliant Amendment (PTOL-324)				
5. Applicant's reply has overcome the following rejection(s)		inpliant / unonumont (1 102 024).				
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 		timely filed amendme	nt canceling the				
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1,5-8,11,14,15,18-21,29,30 and 39-44.	vided below or appended.	Il be entered and an e	explanation of				
Claim(s) withdrawn from consideration: 9,12,13,22-28 and							
AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e).							
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to of showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appea y and was not earlier presented. S	al and/or appellant fai ee 37 CFR 41.33(d)(1	ls to provide a).				
10. ☐ The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attach	ied.				
 The request for reconsideration has been considered bu See Continuation Sheet. 	it does NOT place the application in	n condition for allowar	nce because:				
12. Note the attached Information Disclosure Statement(s). 13. Other:	(PTO/SB/08) Paper No(s)						

Continuation of 11. does NOT place the application in condition for allowance because: Applicant argues that the cited art does not contain figures, that the rejection provides no motivation to combine and no expectation of success and also does not teach or suggest all the limitations. Also, that parallel is art known.

Applicant's arguments haver been fully considered and found persuasive in part.

The 112 second rejection for parallel is withdrawn after consideration of the supplied art Yaresh et al.

The 103 rejection is maintained. The Examiner has looked and the inclusion of figures in reference to Lusky is in error. The limitations are present in the disclosure of Lusky. Lusky teach in Examples 1-3 that BAV3/Ads5 chimera is replication competent in bovine cells and that BAV3 encapsidation signals used in the virus or vector do not encapsidate in human 293 cells. Claims 1, 5, and 6 point out a BAV3 vector as used in the examples. The instant claims do not require that the vector be full length BAV3 but merely a vector. The vector of Lusky acts as a BAV3 vector because it is replication competent in bovine cells. Applicant argues that the reference teaches replication defective Ad vectors which are deleted in E1 region. As pointed out above, adenovirus can be replication competent depending on the cell line used. The instant claims are not limited to particular cell or a method using a particul cell. Applicant also argues about E1 deletions and that they are not replication competent. There is no limitation in the claims requiring the vectors contain or ommit E1 deletions as part of the replication competent phenotype.

The level of skill in the art is high and the use of adenovirus as expression vectors is well known. One of ordinary skill in the art would be able to make a range of adenovirus contructs for expression of heterologous genes. Matthews et al. teaches that introns increase the level of gene expression using an intron is recognized by Matthews (page 351, column 2, middle) and that it is a hybrid intron (page 346, column 1, last full paragraph). Heterologous promoters are used both in Kaufman and Matthews. Kaufman et al. disclose the other features of the intron (Figure 8, splice donar exceptor sites and that the splicing is correct, page 1316, column 1, start of last part paragraph). While the word "strong" is not used, the splicing appears fully functional. Where, as here, the Patent Office lacks the facilities to perform comparisons between the claimed material and prior art materials that reasonably appear to meet the claim limitations, the burden is properly shifted to applicant to distinguish the claimed product from the prior art product. See In re Best, Bolton, and Shaw, 195 USPQ 430 (CCPA 1977); Ex Parte Gray, 10 USPQ2nd 1922 (BPAI 1989).

Thus the rejection is amintained.

12/2/106

BRUCE R. CAMPELL, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

-lampe